Your new experience awaits. Try the new design now and help us make it even better

TECHNOLOGY AND CODE article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1599389

This article is part of the Research TopicExploring Molecular Mechanisms in Cancer through Tumor Molecular PathologyView all 3 articles

A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer

Provisionally accepted
Amith  RangarajanAmith Rangarajan1Ilona  SviezhentsevaIlona Sviezhentseva2Emma  GundersonEmma Gunderson1Yana  PikmanYana Pikman2Matthew  P JacobsonMatthew P Jacobson1Beth  Apsel WingerBeth Apsel Winger1*
  • 1University of California, San Francisco, San Francisco, United States
  • 2Dana–Farber Cancer Institute, Boston, Massachusetts, United States

The final, formatted version of the article will be published soon.

Introduction: Clinical workflows to analyze variants of unknown significance (VUSs) found in clinical next generation sequencing (NGS) are labor intensive, requiring manual analysis of published data for each variant. There is a strong need for tools and resources that provide a consistent way to analyze variants. With the explosion of clinical NGS data and the concurrent availability of protein structures through the Protein Data Bank and protein models through programs such as AlphaFold, there exists an unprecedented opportunity to use structural information to help standardize NGS analysis with the overall goal of advancing personalized cancer therapy. Methods: Using the Catalogue of Somatic Mutations in Cancer (COSMIC), the largest curated database of clinical cancer mutations, we mapped thousands of missense mutations in the kinase and juxtamembrane (JM) domains of 48 receptor tyrosine kinases (RTKs) onto structurally aligned kinase structures, then clustered known activating mutations along with VUSs based on proximity in three-dimensional structure. Using cell-based models we demonstrated that our resource can be used to aid in identification of activating mutations while providing insight into mechanisms of kinase activation and regulation. Results: We provide a database of structurally aligned and functionally annotated mutations that can be used as a tool to evaluate kinase VUSs based on their structural alignment with known activating mutations. The tool can be accessed through a user-friendly website in which one can input a kinase mutation of interest, and the system will output a list of structurally analogous mutations in other kinases, as well as their functional annotations. Discussion: Though our tool is not expected to be used as an isolated source for variant functional prediction, we expect our database will be a valuable addition to the current tools and resources used to analyze clinical NGS, with important clinical implications to guide recommendations for personalized cancer therapy.

Keywords: Cancer, targeted therapy, Molecular pathology, next generation sequencing, kinases, Structural Biology, Variants of unknown significance

Received: 24 Mar 2025; Accepted: 26 Jun 2025.

Copyright: © 2025 Rangarajan, Sviezhentseva, Gunderson, Pikman, Jacobson and Apsel Winger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Beth Apsel Winger, University of California, San Francisco, San Francisco, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.